The story of the erectile dysfunction drug presents a challenging picture for those considering investment. While the initial release generated substantial returns, the lapse of its intellectual property protection https://bookmarkinglog.com/story21670833/the-copyright-and-the-pharmaceutical-industry-a-precarious-bet